NEWS

BioArk is on a roll! The Monthey-based technology site, which celebrates its 20th anniversary this year, inaugurated its third building on Friday.

The pharmaceutical and biotechnology group Lonza has confirmed the extension of a long-term collaboration with a major global biopharmaceutical partner. The agreement will quadruple current bioconjugation capacity at the Ibex facilities in Visp. The new suites are expected to be operational in 2026 and will generate approximately 180 jobs, according to Lonza.

The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…

The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…

Two Swiss jewels in the crown of pharmaceutical subcontracting rank 1st and 6th in the world ranking published by Genetic Engineering & Biotechnology News.  Proof of a booming sector in our canton.

GaDia SA, a Valais-based start-up specializing in the development of diagnostic tests, and HES-SO Valais-Wallis are to collaborate on the development of a new-generation rapid test for the detection of fungal infections such as Invasive Pulmonary Aspergillosis (IPA). This research project is supported by Innosuisse, the Swiss innovation promotion agency, to the tune of CHF 350,000.

Swiss company ten23 health has just announced an increase in capacity for the manufacture of sterile…

Ten23 health, a company based in Basel and on the BioArk in Visp, announces the launch of “quality…

Based at BioArk’s technology site in Monthey and at Monash University in Melbourne, start-up Orio…

Lugaia, an SME based in the Upper Valais and active in the development of sterile packaging solutions…